pRNFL thickness change versus group control in the four quadrants and the 360° average
| Group | 1st group (within 3 months) | 2nd group (3–6 months) | 3rd group (6–9 months) | 4th group (9–12 months) | 5th group (12–24 months) | 6th group (24–60 months) | 7th group (>60 months) |
|---|---|---|---|---|---|---|---|
| RNFL average thickness change versus group control | 6.61% | −17.78%* | −37.63%* | −50.18% | −51.35% | −61.37% | −57.23% |
| RNFL S thickness change versus group control | 12.15% | −12.58%* | −30.36% | −47.81%* | −46.44% | −62.25%* | −53.39% |
| RNFL N thickness change versus group control | 26.13%* | −2.44% | −17.66% | −34.57% | −38.22% | −50.84% | −51.11% |
| RNFL I thickness change versus group control | 10.37% | −11.72% | −40.28%* | −47.79% | −52.72% | −62.89% | −57.69% |
| RNFL T thickness change versus group control | −20.92%* | −44.37%* | −57.58% | −67.20% | −61.71% | −64.77% | −66.34% |
*P<0.05 when compared with the former group.
Date are shown as % change versus group control. Values were compared by one-way analysis of covariance, followed by Bonferroni posthoc test. Sex and age were used as covariates in the analysis.
Group control, healthy control; I, inferior; N, nasal; RNFL, retinal nerve fibre layer; S, superior; T, temporal; 1st group, disease duration ≤3 months; 2nd group, disease duration 3–6 months; 3rd group, disease duration 6–9 months; 4th group, disease duration 9–12 months; 5th group, disease duration 12–24 months; 6th group, disease duration 24–60 months; 7th group: disease duration >60 months.